Carlos Perdomo Selected Research

rufinamide

9/2021	Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022.
6/2019	Novel seizure outcomes in patients with Lennox-Gastaut syndrome: Post hoc analysis of seizure-free days in rufinamide Study 303.
4/2017	Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.
2/2011	A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures.
2/2010	A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures.
8/2009	Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlos Perdomo Research Topics

Disease

6	Sleep Initiation and Maintenance Disorders (Insomnia) 04/2022 - 01/2020
6	Seizures (Absence Seizure) 09/2021 - 08/2009
5	Alzheimer Disease (Alzheimer's Disease) 01/2016 - 03/2003
3	Lennox Gastaut Syndrome 09/2021 - 04/2017
3	Sleepiness 01/2021 - 02/2011
3	Weight Loss (Weight Reduction) 01/2019 - 01/2018
3	Overweight 01/2019 - 01/2018
2	Fatigue 04/2022 - 02/2011
2	Nausea 02/2011 - 08/2009
2	Diplopia (Double Vision) 02/2011 - 08/2009
2	Dizziness (Lightheadedness) 02/2011 - 08/2009
1	Nasopharyngitis 01/2021
1	Headache (Headaches) 01/2021
1	Myocardial Infarction 01/2019
1	Chronic Renal Insufficiency 01/2019
1	Albuminuria 01/2019
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2019
1	Prediabetic State (Prediabetes) 11/2018
1	Type 2 Diabetes Mellitus (MODY) 11/2018
1	Hypoglycemia (Reactive Hypoglycemia) 01/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2018
1	Ataxia (Dyssynergia) 08/2009
1	Dementia (Dementias) 10/2003
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 10/2003

Drug/Important Bio-Agent (IBA)

6	lemborexantIBA 04/2022 - 01/2020
6	rufinamide FDA Link 09/2021 - 08/2009
4	Orexin Receptor AntagonistsIBA 04/2022 - 01/2020
4	Donepezil (Aricept)FDA LinkGeneric 07/2004 - 03/2003
3	5-HT2C Serotonin ReceptorIBA 01/2019 - 01/2018
3	lorcaserinIBA 01/2019 - 01/2018
2	Pharmaceutical PreparationsIBA 01/2021 - 06/2019
2	Anticonvulsants (Antiepileptic Drugs)IBA 02/2011 - 02/2010
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 11/2003 - 10/2003
1	Zolpidem (Ambien)FDA LinkGeneric 01/2021
1	AlbuminsIBA 01/2019
1	CreatinineIBA 01/2019
1	VS 215IBA 11/2018
1	N-acetylaspartate (N-acetyl aspartate)IBA 11/2003
1	Protons (Proton)IBA 11/2003

Therapy/Procedure

4	Therapeutics 01/2016 - 08/2009
1	Aftercare (After-Treatment) 11/2003
1	Activities of Daily Living (ADL) 10/2003